查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1972781

猫科动物药品市场：依治疗领域、产品类型、给药途径及最终用户划分－2026-2032年全球预测

Cat Medicines Market by Therapeutic Area, Product Type, Route Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，猫科动物药品市场价值将达到 166 亿美元，到 2026 年将成长到 182.7 亿美元，到 2032 年将达到 339.4 亿美元，复合年增长率为 10.74%。

主要市场统计数据
基准年 2025 166亿美元
预计年份：2026年 182.7亿美元
预测年份 2032 339.4亿美元
复合年增长率 (%) 10.74%

简洁地介绍了正在重新定义整个兽医生态系统中猫科动物治疗药物的开发、临床预期和商业性可用性的不断演变的驱动因素。

现代猫科动物治疗领域的格局正因科技进步、宠物饲主期望的改变以及新型兽医服务模式的融合而重塑。生物製药的创新、药物製剂的改进以及更精准的给药方法不断涌现，同时，人们对动物福利、合理使用抗生素以及人与动物之间情感纽带的关注也日益增长。精简的供应链和日益复杂的监管环境也提高了产品可靠性和合规性的要求。

生物製药、数位医疗、饲主行为、供应链和法规的现代化推动了猫科动物医疗保健领域的重大变革。

多项变革正在重塑猫科动物药物的发现、研发和给药方式。生物製药和疫苗技术的进步加速了标靶治疗和预防性产品的研发。同时，药物科学的同步发展使得缓释注射剂、口服和外用疗法等更便于饲主使用的製剂成为可能。数位化工具、远端医疗平台和远端监测技术正在改变兽医诊断和管理慢性疾病的方式，为提高用药依从性和治疗后后续观察创造了新的途径。

2025年美国新关税对猫科动物治疗药物采购、生产及商业性弹性策略的影响

美国2025年实施的新关税措施，正对猫科动物製药业的企业采购、生产决策和成本结构产生连锁反应。此前，这些企业受益于与跨国供应商建立的跨境供应链，但关税的提高迫使它们重新评估原产地策略，尽可能优先考虑本地生产，并修订供应商合约以降低成本波动风险。为此，企业正加速推动近岸外包和供应商多元化，以减少对单一贸易路线的依赖。

根据治疗领域、产品类型、给药途径和最终用户群体，分析猫科动物治疗的商业性和临床意义。

对治疗领域的细分检验揭示了每个类别独特的创新和商业化路径，包括麻醉剂、抗感染药、抗发炎药、内分泌治疗药物、驱虫药和疫苗。在麻醉剂领域，全身麻醉和局部麻醉的差异影响製剂的选择和手术全期通讯协定；局部麻醉剂适用于门诊病人，而全身麻醉剂则在复杂的手术中发挥其特殊作用。抗感染剂分为注射用抗生素和口服抗生素，影响处方模式、合理用药方案、病人用药责任。抗发炎药物分为非类固醇消炎剂（NSAIDs）和类固醇，每种药物都有其独特的安全性特征和监测要求，这些因素决定了产品标籤和兽医指导政策。内分泌治疗药物分为胰岛素製剂和甲状腺製剂，需要不同的给药系统和药物支持，尤其是在慢性病治疗中。驱虫药依其剂型分为注射剂、口服剂和外用剂，这导致患者的购买行为和用药依从性有差异。疫苗则分为灭活疫苗和活病毒疫苗，这导致其冷藏管理、储存期限和接种程序有差异。

美洲、欧洲、中东和非洲以及亚太地区的区域监管、分销和需求趋势及其对商业策略的影响。

区域趋势对美洲、欧洲、中东、非洲和亚太地区的监管、分销模式和临床实践标准有显着影响。在美洲，完善的兽医网络、宠物饲主较高的消费能力以及有利于多通路策略的复杂经销伙伴塑造了市场环境。企业通常优先考虑遵守国家监管机构的规定以及物流基础设施的建设，以确保产品品质。在欧洲、中东和非洲，分散的管理体制和多样化的临床实践标准要求企业采取个人化的市场准入策略。尤其需要关注欧洲内部的监管协调工作以及中东和非洲特定市场面临的物流挑战。在亚太地区，快速的都市化、可支配收入的增长以及伴侣动物服务的扩张正在加速对先进治疗药物的需求，但各地区在报销制度、许可途径和低温运输能力方面存在差异。

竞争与伙伴关係的动态如何影响猫科动物治疗整个价值链的创新、生产柔软性和分销效率。

猫科动物治疗领域的竞争格局呈现出多元化的特点，既有成熟的动物用药品公司，也有专注生物製药研发的专业公司，还有灵活的契约製造，以及新兴的数位医疗领域的参与企业。成熟公司利用其规模和全球分销网络，维持丰富的产品系列和完善的药物监测系统。同时，专业公司正致力于研发差异化技术，例如新型疫苗平台、缓释注射剂和标靶内分泌疗法。契约製造组织（CMO）和製剂专家正日益成为重要的合作伙伴，他们能够柔软性进行无菌和非无菌生产，并加快新产品进入临床试验阶段的速度。

产业领导者应采取具有重大影响力的策略行动和营运重点，以增强韧性、实现商业化并提供长期治疗价值。

产业领导者应优先采取一系列营运和策略行动，以在持续的市场动盪中创造价值。首先，将研发投资集中在临床需求与可行差异化结合的高价值治疗领域，将有助于提高研发效率和商业性价值。其次，透过投资地理多元化、检验的二级供应商以及契约製造，降低供应链风险，进而减轻关税和物流衝击带来的影响。第三，透过投资开发更方便患者使用的剂型和给药工具，提高产品的易用性，可以显着提高患者的用药依从性和品牌偏好。

高度透明、以从业者观点的研究方法，将二手监管和科学记录与一手访谈以及交叉检验的交易和安全数据相结合。

本分析所依据的研究结合了结构化的二手资料研究、一手定性访谈以及多方资讯来源三角检验，从而对猫科动物治疗药物的市场趋势进行了全面而深入的分析。二级资讯来源包括监管文件、临床试验註册资讯、专利文件、生产和分销指南以及公开的产品标籤和安全资讯。研究人员对这些资料进行了系统性的审查，以识别技术趋势、监管趋势和产品层面的差异化因素。

对科学创新、供应链韧性和商业性可行性之间的相互作用进行全面分析。这些因素将决定猫科动物治疗领域的长期成功。

分析表明，猫科动物治疗领域正处于转折点。科学进步、终端用户期望的改变以及政策的调整相互交织，既带来了机会，也带来了挑战。治疗差异化越来越依赖製剂技术、生物製药和疫苗平台的创新性，以及能否根据饲主的日常习惯和兽医的工作流程提供治疗。贸易政策和供应链的实际情况正从后勤部门考量转变为影响采购、定价和生产力计画的核心策略工具。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：猫科动物药品市场：依治疗领域划分

  • 麻醉剂
    • 一般的
    • 局部的
  • 抗感染药物
    • 注射用抗生素
    • 口服抗生素
  • 抗发炎药
    • 非类固醇消炎剂（NSAIDs）
    • 类固醇
  • 内分泌系统
    • 胰岛素
    • 甲状腺
  • 杀虫剂
    • 注射药物
    • 口服
    • 外用药物
  • 疫苗
    • 失活
    • 活病毒疫苗

第九章：猫用药品市场：依产品类型划分

  • 注射药物
    • 肌肉内注射
    • 静脉注射
    • 皮下注射
  • 液体
    • 口服液体药物
    • 悬浮液
    • 糖浆
  • 固态剂型
    • 胶囊
    • 粉末
    • 药片
  • 外部产品
    • 软膏
    • 洗髮精
    • 点涂治疗药物

第十章：猫用药品市场：依给药途径划分

  • 口服
    • 口服液体药物
    • 口服固态剂型
  • 肠外
    • 肌肉内注射
    • 静脉注射
    • 皮下注射
  • 外用药物
    • 局部应用
    • 经皮吸收

第十一章：猫用药品市场：依最终用户划分

  • 宠物饲主
  • 兽医专家
    • 医院和诊所
    • 私人执业兽医

第十二章：猫用药品市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：猫用药品市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：猫用药品市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国猫科动物药品市场

第十六章：中国猫药市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Bimeda, Inc.
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale SA
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Heska Corporation
  • Hester Biosciences Ltd.
  • IDEXX Laboratories Inc.
  • Merck & Co., Inc.
  • Phibro Animal Health Corporation
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-9A6A6F297DE3

The Cat Medicines Market was valued at USD 16.60 billion in 2025 and is projected to grow to USD 18.27 billion in 2026, with a CAGR of 10.74%, reaching USD 33.94 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.60 billion
Estimated Year [2026] USD 18.27 billion
Forecast Year [2032] USD 33.94 billion
CAGR (%) 10.74%

A concise primer on the shifting drivers redefining feline therapeutic development, clinical expectations, and commercial delivery across the veterinary ecosystem

The contemporary landscape of feline therapeutics is being reshaped by converging scientific advances, evolving pet owner expectations, and new models of veterinary care delivery. Biological innovations, refined formulations, and more precise dosing modalities are emerging alongside heightened attention to animal welfare, antimicrobial stewardship, and the human-animal bond. At the same time, supply chain rationalization and a more complex regulatory environment are raising the bar for product reliability and compliance.

Transitioning from conventional product development paradigms, stakeholders across the value chain-from pharmaceutical developers and contract manufacturers to distributors and veterinary practitioners-are adapting to a faster cadence of innovation and a demand for differentiated value. This introduction frames the broader market drivers and the strategic tensions that follow: balancing efficacy and safety, meeting diverse end-user needs, and aligning commercial models with shifting clinical and consumer behaviors. These dynamics set the stage for deeper analysis across therapeutic categories, product formats, distribution channels, and regional nuances that follow in subsequent sections.

Key transformative shifts in feline medicine driven by biologics, digital health, owner behavior, and supply chain and regulatory modernization

Several transformative shifts are redefining how feline medicines are discovered, developed, and delivered. Advances in biologics and vaccine technologies have accelerated the development of targeted therapeutics and preventative products, while parallel progress in formulation science has enabled extended-release injectables and owner-friendly oral or topical treatments. Digital tools, telehealth platforms, and remote monitoring technologies are changing how veterinarians diagnose and manage chronic conditions, creating new touchpoints for adherence and post-treatment surveillance.

Behavioral and demographic trends among pet owners are also significant: greater willingness to invest in advanced care, demand for convenience in dosing and administration, and stronger interest in wellbeing and preventative medicine. Supply chain modernization and regulatory harmonization efforts are encouraging higher manufacturing quality and transparency, but they also introduce complexity that companies must manage. Taken together, these shifts are prompting incumbents and new entrants to re-evaluate R&D priorities, distribution partnerships, and commercial models to remain responsive to a rapidly evolving ecosystem.

How new United States tariff measures are reshaping sourcing, manufacturing, and commercial resilience strategies for feline therapeutics throughout 2025

The introduction of new tariff measures in the United States during 2025 is creating a ripple effect across sourcing, manufacturing decisions, and cost structures for companies operating in the feline medicines space. Where previously multinational suppliers benefited from established cross-border supply chains, rising duties are prompting firms to re-examine origin-of-goods strategies, prioritize local production where feasible, and reassess supplier contracts to mitigate cost volatility. As firms respond, there is an observable acceleration in nearshoring and diversification of supplier bases to limit exposure to a single trade corridor.

Pharmaceutical-grade raw materials, specialized excipients, and certain finished formulations that move across borders are particularly sensitive to tariff-driven cost pressures. In response, organizations are adjusting procurement protocols, expanding long-term supplier agreements with price corridors, and investing in manufacturing resilience such as dual sourcing and flexible production lines. These strategic shifts are also influencing pricing negotiations with distributors and veterinary practices, procurement cycles within veterinary institutions, and investment considerations for manufacturing capacity expansions. Regulatory compliance and customs planning have become more central to commercial strategies, and companies that integrate trade policy analysis with operational planning are better positioned to sustain product availability and margin integrity.

Strategic commercial and clinical implications derived from therapeutic area, product type, administration route, and end user segmentation for feline therapeutics

Examining therapeutic area segmentation reveals distinct innovation and commercialization pathways across categories such as anesthetics, anti-infectives, anti-inflammatories, endocrine therapies, parasiticides, and vaccines. Within anesthetics, the differentiation between general and local approaches affects formulation choices and perioperative protocols, with local agents enabling outpatient-friendly procedures and general agents retaining a specialized role in complex surgeries. Anti-infectives are bifurcated between injectable antibiotics and oral antibiotics, which influence prescribing patterns, stewardship programs, and client administration responsibilities. Anti-inflammatories split into NSAIDs and steroids, each presenting unique safety and monitoring profiles that inform labeling and veterinarian guidance. Endocrine therapies divided into insulin and thyroid products require divergent delivery systems and adherence support, especially for chronic care pathways. Parasiticides differentiated by injectable, oral, and topical modalities create varied purchase and compliance behaviors, while vaccines categorized as inactivated or live shape refrigeration logistics, shelf life, and vaccination schedules.

Looking at product type segmentation, injectable products-further distinguished by intramuscular, intravenous, and subcutaneous routes-demand different clinical settings and training, affecting where and how they are administered. Liquid dosage forms encompassing oral solutions, suspensions, and syrups are often favored for ease of use in certain populations, while solid dosage forms such as capsules, powders, and tablets support stability and precise dosing. Topical products including ointments, shampoos, and spot-on treatments align closely with owner-led administration and retail distribution channels. Route of administration segmentation highlights oral, parenteral, and topical pathways, each with subcategories influencing adherence, pharmacokinetics, and product design such as local topical versus transdermal delivery or liquid oral versus solid oral formulations. Finally, end-user segmentation differentiates between pet owners and veterinary professionals, with the latter further split into hospital clinics and private practices; this distinction underscores divergent purchasing behaviors, clinical competencies, and communication needs that influence product positioning, educational initiatives, and support services.

Regional regulatory, distribution, and demand dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific and their implications for commercial strategy

Regional dynamics exert a powerful influence on regulation, distribution models, and clinical practice standards across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, the landscape is shaped by sophisticated veterinary networks, strong pet owner spending, and complex distribution partnerships that favor multi-channel strategies; companies often prioritize compliance with national regulatory authorities and logistics infrastructure to maintain product integrity. In Europe, Middle East & Africa, fragmented regulatory regimes and diverse clinical practice norms require tailored market entry approaches, with particular attention to harmonization efforts within European jurisdictions and logistics challenges in certain Middle Eastern and African markets. In Asia-Pacific, rapid urbanization, rising disposable income, and growing penetration of companion animal services are accelerating demand for advanced therapeutics, but the region also presents heterogeneity in reimbursement, licensing pathways, and cold-chain capabilities.

These regional differences have practical implications for portfolio prioritization, clinical trial design, and distribution networks. Supply chain resilience measures, such as regional production hubs and localized packaging or labelling, are increasingly important to meet regulatory and logistical demands. Additionally, educational programs and marketing must be regionally calibrated to account for local clinical protocols, cultural attitudes toward pets, and the relative maturity of veterinary services. Companies that align product design, compliance strategies, and go-to-market models with these regional realities can more effectively convert global R&D into sustainable commercial performance across diverse territories.

Competitive landscape and partnership dynamics shaping innovation, manufacturing flexibility, and distribution effectiveness across the feline therapeutic value chain

The competitive landscape in feline therapeutics is characterized by a mix of long-established animal health companies, specialist biologics developers, agile contract manufacturers, and an expanding cohort of digital health entrants. Incumbent firms continue to leverage scale and global distribution reach to support wide product portfolios and robust pharmacovigilance systems. Meanwhile, specialist players are advancing differentiated technologies such as novel vaccine platforms, extended-release injectables, and targeted endocrine therapies. Contract manufacturing organizations and formulation specialists are increasingly important partners, enabling faster time-to-clinic for novel products while offering manufacturing flexibility across sterile and non-sterile processes.

Distribution partners, including veterinary wholesalers and retail chains, play a critical role in maintaining product availability and supporting education at the point of care. Digital-first companies focused on telehealth, treatment adherence platforms, and remote monitoring are reshaping how products are prescribed and supported post-sale. Across this landscape, winners are those that integrate clinical evidence generation with commercialization capabilities, maintain rigorous quality controls, and invest in customer-centric services such as practitioner training, owner adherence supports, and transparent supply chain practices. Strategic alliances, licensing deals, and targeted acquisitions remain common mechanisms for accessing complementary capabilities and accelerating pipeline maturation.

High-impact strategic actions and operational priorities that industry leaders should adopt to strengthen resilience, commercialization, and long-term therapeutic value delivery

Industry leaders should prioritize a set of operational and strategic actions to capture value amid ongoing disruption. First, aligning R&D investment with high-value therapeutic niches-where clinical need and feasible differentiation intersect-will improve development efficiency and commercial relevance. Second, de-risking supply chains through geographic diversification, validated secondary suppliers, and investments in contract manufacturing capacity will reduce exposure to tariff and logistics shocks. Third, enhancing product usability by investing in owner-friendly dose forms and administration tools can materially improve adherence and brand preference.

In parallel, companies should formalize digital engagement strategies that combine practitioner education, telemedicine integrations, and adherence monitoring to support long-term therapeutic outcomes. Regulatory and quality teams must be integrated early into product development to streamline approvals, labeling, and pharmacovigilance. Finally, commercial models should be tailored to end-user segments: sophisticated, evidence-focused engagement with veterinary professionals and convenience-plus-education approaches for owners. Executing these recommendations requires cross-functional governance, outcome-oriented KPIs, and a willingness to pilot novel distribution and service models that can scale rapidly when validated.

A transparent and practitioner-informed research approach combining secondary regulatory and scientific records with primary interviews and cross-validated trade and safety data

The research behind this analysis combines structured secondary research, primary qualitative interviews, and triangulation across multiple information sources to produce a robust view of the feline therapeutics landscape. Secondary inputs include regulatory filings, clinical trial registries, patent literature, manufacturing and distribution guidelines, and publicly available product labeling and safety communications. These materials were systematically reviewed to identify technological trends, regulatory shifts, and product-level differentiation.

Primary research consisted of in-depth interviews with veterinary clinicians across hospital clinics and private practices, procurement managers at distribution partners, R&D and manufacturing leads at pharmaceutical and contract organizations, and specialist veterinarians focusing on endocrinology, parasitology, and infectious disease. Where appropriate, findings were validated through cross-comparison with trade data, customs filings, and pharmacovigilance reports to ensure consistency and identify emerging patterns. Analytical frameworks applied include value-chain mapping, risk exposure analysis for supply and tariff impacts, and segmentation-driven persona development for end users. Together, these methodological steps support a defensible, practitioner-informed account of current dynamics and strategic implications.

Concluding synthesis on the interplay between scientific innovation, supply chain resilience, and commercial execution that will determine long-term success in feline therapeutics

This analysis demonstrates that the feline therapeutics sector is at an inflection point where scientific momentum, changing end-user expectations, and policy shifts intersect to create both opportunity and complexity. Therapeutic differentiation increasingly depends on formulation ingenuity, biologic and vaccine platforms, and the ability to deliver treatments in ways that align with owner routines and veterinary workflows. Trade policy and supply chain realities have moved from back-office considerations to central strategic levers that influence sourcing, pricing, and capacity planning.

Organizations that succeed will be those that integrate clinical evidence generation with flexible manufacturing and distribution strategies, embrace digital channels for practitioner and owner engagement, and proactively mitigate trade and regulatory risks. Moving forward, cross-functional collaboration-spanning R&D, regulatory, manufacturing, and commercial teams-will be essential to convert innovation into durable clinical impact and sustainable business performance. The priorities outlined here provide a blueprint for executives seeking to navigate the near-term disruptions while positioning for long-term growth and resilience.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cat Medicines Market, by Therapeutic Area

  • 8.1. Anesthetics
    • 8.1.1. General
    • 8.1.2. Local
  • 8.2. Anti-Infectives
    • 8.2.1. Injectable Antibiotics
    • 8.2.2. Oral Antibiotics
  • 8.3. Anti-Inflammatories
    • 8.3.1. NSAIDs
    • 8.3.2. Steroids
  • 8.4. Endocrine
    • 8.4.1. Insulin
    • 8.4.2. Thyroid
  • 8.5. Parasiticides
    • 8.5.1. Injectable
    • 8.5.2. Oral
    • 8.5.3. Topical
  • 8.6. Vaccines
    • 8.6.1. Inactivated
    • 8.6.2. Live

9. Cat Medicines Market, by Product Type

  • 9.1. Injectable Products
    • 9.1.1. Intramuscular
    • 9.1.2. Intravenous
    • 9.1.3. Subcutaneous
  • 9.2. Liquid Dosage Forms
    • 9.2.1. Oral Solutions
    • 9.2.2. Suspensions
    • 9.2.3. Syrups
  • 9.3. Solid Dosage Forms
    • 9.3.1. Capsules
    • 9.3.2. Powders
    • 9.3.3. Tablets
  • 9.4. Topical Products
    • 9.4.1. Ointments
    • 9.4.2. Shampoos
    • 9.4.3. Spot-On Treatments

10. Cat Medicines Market, by Route Of Administration

  • 10.1. Oral
    • 10.1.1. Liquid Oral
    • 10.1.2. Solid Oral
  • 10.2. Parenteral
    • 10.2.1. Intramuscular
    • 10.2.2. Intravenous
    • 10.2.3. Subcutaneous
  • 10.3. Topical
    • 10.3.1. Local Topical
    • 10.3.2. Transdermal

11. Cat Medicines Market, by End User

  • 11.1. Pet Owners
  • 11.2. Veterinary Professionals
    • 11.2.1. Hospital Clinics
    • 11.2.2. Private Practices

12. Cat Medicines Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cat Medicines Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cat Medicines Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Cat Medicines Market

16. China Cat Medicines Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Bimeda, Inc.
  • 17.6. Boehringer Ingelheim International GmbH
  • 17.7. Ceva Sante Animale S.A.
  • 17.8. Dechra Pharmaceuticals PLC
  • 17.9. Elanco Animal Health Incorporated
  • 17.10. Heska Corporation
  • 17.11. Hester Biosciences Ltd.
  • 17.12. IDEXX Laboratories Inc.
  • 17.13. Merck & Co., Inc.
  • 17.14. Phibro Animal Health Corporation
  • 17.15. Vetoquinol S.A.
  • 17.16. Virbac S.A.
  • 17.17. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CAT MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CAT MEDICINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CAT MEDICINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CAT MEDICINES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CAT MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CAT MEDICINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CAT MEDICINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CAT MEDICINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CAT MEDICINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CAT MEDICINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CAT MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CAT MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CAT MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CAT MEDICINES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CAT MEDICINES MARKET SIZE, BY ANESTHETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CAT MEDICINES MARKET SIZE, BY ANESTHETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CAT MEDICINES MARKET SIZE, BY ANESTHETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CAT MEDICINES MARKET SIZE, BY ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CAT MEDICINES MARKET SIZE, BY GENERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CAT MEDICINES MARKET SIZE, BY GENERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CAT MEDICINES MARKET SIZE, BY GENERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CAT MEDICINES MARKET SIZE, BY LOCAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CAT MEDICINES MARKET SIZE, BY LOCAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CAT MEDICINES MARKET SIZE, BY LOCAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CAT MEDICINES MARKET SIZE, BY INJECTABLE ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CAT MEDICINES MARKET SIZE, BY INJECTABLE ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CAT MEDICINES MARKET SIZE, BY INJECTABLE ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CAT MEDICINES MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CAT MEDICINES MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CAT MEDICINES MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CAT MEDICINES MARKET SIZE, BY STEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CAT MEDICINES MARKET SIZE, BY STEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CAT MEDICINES MARKET SIZE, BY STEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CAT MEDICINES MARKET SIZE, BY ENDOCRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CAT MEDICINES MARKET SIZE, BY ENDOCRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CAT MEDICINES MARKET SIZE, BY ENDOCRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CAT MEDICINES MARKET SIZE, BY ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CAT MEDICINES MARKET SIZE, BY INSULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CAT MEDICINES MARKET SIZE, BY INSULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CAT MEDICINES MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CAT MEDICINES MARKET SIZE, BY THYROID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CAT MEDICINES MARKET SIZE, BY THYROID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CAT MEDICINES MARKET SIZE, BY THYROID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CAT MEDICINES MARKET SIZE, BY PARASITICIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CAT MEDICINES MARKET SIZE, BY PARASITICIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CAT MEDICINES MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CAT MEDICINES MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CAT MEDICINES MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CAT MEDICINES MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CAT MEDICINES MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CAT MEDICINES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CAT MEDICINES MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CAT MEDICINES MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CAT MEDICINES MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CAT MEDICINES MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CAT MEDICINES MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CAT MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CAT MEDICINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CAT MEDICINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CAT MEDICINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CAT MEDICINES MARKET SIZE, BY LIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CAT MEDICINES MARKET SIZE, BY LIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CAT MEDICINES MARKET SIZE, BY LIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CAT MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CAT MEDICINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CAT MEDICINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CAT MEDICINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CAT MEDICINES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CAT MEDICINES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CAT MEDICINES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CAT MEDICINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CAT MEDICINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CAT MEDICINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CAT MEDICINES MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CAT MEDICINES MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CAT MEDICINES MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CAT MEDICINES MARKET SIZE, BY SYRUPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CAT MEDICINES MARKET SIZE, BY SYRUPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CAT MEDICINES MARKET SIZE, BY SYRUPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CAT MEDICINES MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CAT MEDICINES MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CAT MEDICINES MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CAT MEDICINES MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CAT MEDICINES MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CAT MEDICINES MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CAT MEDICINES MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CAT MEDICINES MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CAT MEDICINES MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CAT MEDICINES MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CAT MEDICINES MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CAT MEDICINES MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CAT MEDICINES MARKET SIZE, BY SHAMPOOS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CAT MEDICINES MARKET SIZE, BY SHAMPOOS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CAT MEDICINES MARKET SIZE, BY SHAMPOOS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CAT MEDICINES MARKET SIZE, BY SPOT-ON TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CAT MEDICINES MARKET SIZE, BY SPOT-ON TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CAT MEDICINES MARKET SIZE, BY SPOT-ON TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CAT MEDICINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CAT MEDICINES MARKET SIZE, BY LIQUID ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CAT MEDICINES MARKET SIZE, BY LIQUID ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CAT MEDICINES MARKET SIZE, BY LIQUID ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CAT MEDICINES MARKET SIZE, BY SOLID ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CAT MEDICINES MARKET SIZE, BY SOLID ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CAT MEDICINES MARKET SIZE, BY SOLID ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CAT MEDICINES MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CAT MEDICINES MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CAT MEDICINES MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CAT MEDICINES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CAT MEDICINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CAT MEDICINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CAT MEDICINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CAT MEDICINES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CAT MEDICINES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CAT MEDICINES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CAT MEDICINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CAT MEDICINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CAT MEDICINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CAT MEDICINES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CAT MEDICINES MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CAT MEDICINES MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CAT MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CAT MEDICINES MARKET SIZE, BY LOCAL TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CAT MEDICINES MARKET SIZE, BY LOCAL TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CAT MEDICINES MARKET SIZE, BY LOCAL TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CAT MEDICINES MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CAT MEDICINES MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CAT MEDICINES MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CAT MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CAT MEDICINES MARKET SIZE, BY PET OWNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CAT MEDICINES MARKET SIZE, BY PET OWNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CAT MEDICINES MARKET SIZE, BY PET OWNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CAT MEDICINES MARKET SIZE, BY HOSPITAL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL CAT MEDICINES MARKET SIZE, BY HOSPITAL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL CAT MEDICINES MARKET SIZE, BY HOSPITAL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CAT MEDICINES MARKET SIZE, BY PRIVATE PRACTICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CAT MEDICINES MARKET SIZE, BY PRIVATE PRACTICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL CAT MEDICINES MARKET SIZE, BY PRIVATE PRACTICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL CAT MEDICINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS CAT MEDICINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS CAT MEDICINES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS CAT MEDICINES MARKET SIZE, BY ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS CAT MEDICINES MARKET SIZE, BY ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS CAT MEDICINES MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS CAT MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS CAT MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS CAT MEDICINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS CAT MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS CAT MEDICINES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS CAT MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS CAT MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. AMERICAS CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE CAT MEDICINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE CAT MEDICINES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE CAT MEDICINES MARKET SIZE, BY ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE CAT MEDICINES MARKET SIZE, BY ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE CAT MEDICINES MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE CAT MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE CAT MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE CAT MEDICINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE CAT MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE CAT MEDICINES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE CAT MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE CAT MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 276. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 278. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 280. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA CAT MEDICINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA CAT MEDICINES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA CAT MEDICINES MARKET SIZE, BY ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA CAT MEDICINES MARKET SIZE, BY ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA CAT MEDICINES MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 289. AFRICA CAT MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 290. AFRICA CAT MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. AFRICA CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 292. AFRICA CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 293. AFRICA CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 294. AFRICA CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 295. AFRICA CAT MEDICINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 296. AFRICA CAT MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 297. AFRICA CAT MEDICINES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 298. AFRICA CAT MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 299. AFRICA CAT MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. AFRICA CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 317. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 318. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 319. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 320. GLOBAL CAT MEDICINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 321. ASEAN CAT MEDICINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 322. ASEAN CAT MEDICINES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 323. ASEAN CAT MEDICINES MARKET SIZE, BY ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 324. ASEAN CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 325. ASEAN CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 326. ASEAN CAT MEDICINES MARKET SIZE, BY ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 327. ASEAN CAT MEDICINES MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 328. ASEAN CAT MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 329. ASEAN CAT MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 330. ASEAN CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 331. ASEAN CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 332. ASEAN CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 333. ASEAN CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 334. ASEAN CAT MEDICINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 335. ASEAN CAT MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 336. ASEAN CAT MEDICINES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 337. ASEAN CAT MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 338. ASEAN CAT MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 339. ASEAN CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 340. GCC CAT MEDICINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 341. GCC CAT MEDICINES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 342. GCC CAT MEDICINES MARKET SIZE, BY ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 343. GCC CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 344. GCC CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 345. GCC CAT MEDICINES MARKET SIZE, BY ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 346. GCC CAT MEDICINES MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 347. GCC CAT MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 348. GCC CAT MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 349. GCC CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 350. GCC CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 351. GCC CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILL